Gene-editing expert
RS Genomics, formed to provide broad access to CRISPR/Cas9 IP, has appointed Eric Rhodes as its new CEO. He joins the company from Horizon Discovery where he held the role of Senior Vice President of R&D and Chief Technology Officer.
Rhodes holds a degree in microbiology and immunology from the University of California, Berkeley. Over the course of his career, he held various positions focused on gene editing technologies including the positions of Director Business Development at Sigma-Aldrich and Vice President Business Development & Alliance Management at Sangamo Biosciences.
At ERS Genomics, Rhodes succeeds founder Shaun Foy, who will in turn become Chairman of the Board of Directors.
Eppendorf
NOD-Proteindesign.Andreas Heddergott/TUM.jpg
Certest